Skip to main content
main-content

Other medication classes used in diabetes

medwireNews

01-31-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

12-06-2019 | Lipid-lowering medications | News

Cholesterol levels predict vascular events decades in advance

A major study shows that non-high-density lipoprotein levels predict atherosclerosis events over a 30-year timescale.

10-24-2019 | Hypertension | News

Bedtime hypertension medication best for averting CV events

A large randomized trial may have settled the question of whether it is best to take blood pressure medications in the morning or evening.

09-20-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

06-11-2019 | Glucagon | ADA 2019 | News

Phase III data support dasiglucagon use for severe hypoglycemia

Dasiglucagon has potential as a fast, effective treatment for severe hypoglycemia in patients with type 1 diabetes, show phase III study data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

04-11-2019 | Lipid-lowering medications | News

BANTING confirms evolocumab benefits in type 2 diabetes

The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.

01-30-2019 | Retinopathy | News

Possible retinopathy benefits with statins for diabetes patients with dyslipidemia

A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

11-08-2018 | Nephropathy | News

Novel VAP-1 inhibitor shows promise for diabetic kidney disease

The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

05-25-2018 | Hypoglycemia | Highlight | News

Mini-dose glucagon could help protect against exercise-induced hypoglycemia

Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.

04-18-2018 | Nephropathy | News

Neprilysin inhibition appears beneficial in diabetic kidney disease

Secondary analysis of the PARADIGM-HF trial shows that the adverse effects of diabetes on kidney function can be ameliorated by a neprilysin inhibitor.

03-01-2018 | Lipid-lowering medications | News

Fenofibrate produces large gout risk reduction in diabetes patients

The anti-cholesterol medication fenofibrate significantly reduces uric acid levels and more than halves the risk for gout in patients with type 2 diabetes, shows an analysis of the FIELD cohort.

01-03-2018 | Glucagon | News

Glucagon use restrictions compromising prehospital hypoglycemia treatment in USA

The widespread bar on glucagon administration by basic providers of emergency medicine in the USA may prevent its use in three-quarters of cases in which it is needed, say researchers.

12-12-2017 | Anti-hypertensive medications | News

Intensive BP treatment back on table for diabetes patients

Intensive blood pressure management benefits patients whether or not they have diabetes and regardless of their baseline level of cardiovascular disease risk, shows a pooled analysis of the SPRINT and ACCORD-BP trials.

11-10-2017 | Nephropathy | News

Salt restriction boosts losartan benefits in type 2 diabetes

Finding from the PROCEED trial show that dietary salt restriction helps to reduce albuminuria in patients with type 2 diabetes taking losartan, the investigators report in The Lancet Diabetes & Endocrinology.

11-01-2017 | Adolescents | News

No renal benefits of ACE inhibitor, statin treatment in adolescents with type 1 diabetes

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

09-14-2017 | PCSK9 inhibitors | EASD 2017 | News

Alirocumab dyslipidemia benefits extended to type 1 patients

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

08-24-2017 | Lipid-lowering medications | News

PCSK9 inhibitors not cost effective

An analysis in JAMA shows that the price of PCSK9 inhibitors, recently shown to be effective against diabetic dyslipidemia, will need to fall by nearly three-quarters before they can be considered cost-effective even in high-risk patients with established cardiovascular disease.

Image Credits